100 related articles for article (PubMed ID: 6574535)
41. Diagnosis and drug therapy of prolactinoma.
Ciccarelli E; Camanni F
Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
[TBL] [Abstract][Full Text] [Related]
42. Clinical response and plasma haloperidol levels in chronic and subchronic schizophrenia.
Santos JL; Cabranes JA; Vazquez C; Fuentenebro F; Almoguera I; Ramos JA
Biol Psychiatry; 1989 Aug; 26(4):381-8. PubMed ID: 2669981
[TBL] [Abstract][Full Text] [Related]
43. Bromocriptine for "negative" schizophrenia.
Levi-Minzi S; Bermanzohn PC; Siris SG
Compr Psychiatry; 1991; 32(3):210-6. PubMed ID: 1679383
[TBL] [Abstract][Full Text] [Related]
44. [Use of haloperidol in high doses in schizophrenia. Clinical, biochemical and pharmacokinetic study].
Scatton B; Zarifian E; Bianchetti G; Cuche H; Loo H; Morselli PL
Encephale; 1982; 8(1):1-8. PubMed ID: 7094868
[TBL] [Abstract][Full Text] [Related]
45. Effect of bromocriptine on antipsychotic drug-induced hyperprolactinemia: eight-week randomized, single-blind, placebo-controlled, multicenter study.
Lee MS; Song HC; An H; Yang J; Ko YH; Jung IK; Joe SH
Psychiatry Clin Neurosci; 2010 Feb; 64(1):19-27. PubMed ID: 19968833
[TBL] [Abstract][Full Text] [Related]
46. Neuroendocrine serotonergic and dopaminergic responsivity in male schizophrenic patients during treatment with neuroleptics and after switch to risperidone.
Markianos M; Hatzimanolis J; Lykouras L
Psychopharmacology (Berl); 2001 Aug; 157(1):55-9. PubMed ID: 11512043
[TBL] [Abstract][Full Text] [Related]
47. Prolactin response to low-dose haloperidol challenge in schizophrenic, non-schizophrenic psychotic, and control subjects.
Copolov DL; Keks NA; Kulkarni J; Singh BS; McKenzie D; McGorry P; Hill C
Psychoneuroendocrinology; 1990; 15(3):225-31. PubMed ID: 2255750
[TBL] [Abstract][Full Text] [Related]
48. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia.
David SR; Taylor CC; Kinon BJ; Breier A
Clin Ther; 2000 Sep; 22(9):1085-96. PubMed ID: 11048906
[TBL] [Abstract][Full Text] [Related]
49. Long-lasting suppression of prolactin secretion and rapid shrinkage of prolactinomas after a long-acting, injectable form of bromocriptine.
Montini M; Pagani G; Gianola D; Pagani MD; Salmoiraghi M; Ferrari L; Lancranjan I
J Clin Endocrinol Metab; 1986 Jul; 63(1):266-8. PubMed ID: 3711262
[TBL] [Abstract][Full Text] [Related]
50. Plasma prolactin as a predictor of relapse in drug-free schizophrenic outpatients.
Kirkpatrick B; Carpenter WT; Maeda K; Buchanan RW; Breier A; Tamminga CA
Biol Psychiatry; 1992 Dec; 32(11):1049-54. PubMed ID: 1467385
[TBL] [Abstract][Full Text] [Related]
51. Hyperprolactinemic response after bromocriptine withdrawal in women with prolactin-secreting pituitary tumors.
Maxson WS; Dudzinski M; Handwerger SH; Hammond CB
Fertil Steril; 1984 Feb; 41(2):218-23. PubMed ID: 6698215
[TBL] [Abstract][Full Text] [Related]
52. Serum haloperidol determinations in psychiatric patients. Comparison of methods and correlation with serum prolactin level.
Rubin RT; Forsman A; Heykants J; Ohman R; Tower B; Michiels M
Arch Gen Psychiatry; 1980 Sep; 37(9):1069-74. PubMed ID: 7416906
[TBL] [Abstract][Full Text] [Related]
53. Coadministration of fluvoxamine increases serum concentrations of haloperidol.
Daniel DG; Randolph C; Jaskiw G; Handel S; Williams T; Abi-Dargham A; Shoaf S; Egan M; Elkashef A; Liboff S
J Clin Psychopharmacol; 1994 Oct; 14(5):340-3. PubMed ID: 7806690
[TBL] [Abstract][Full Text] [Related]
54. Prolactin levels in male schizophrenic patients treated with risperidone and haloperidol: a double-blind and randomized study.
Zhang XY; Zhou DF; Cao LY; Zhang PY; Wu GY; Shen YC
Psychopharmacology (Berl); 2005 Feb; 178(1):35-40. PubMed ID: 15289996
[TBL] [Abstract][Full Text] [Related]
55. Haloperidol: therapeutic window in schizophrenia.
Palao DJ; Arauxo A; Brunet M; Bernardo M; Haro JM; Ferrer J; Gonzalez-Monclus E
J Clin Psychopharmacol; 1994 Oct; 14(5):303-10. PubMed ID: 7806684
[TBL] [Abstract][Full Text] [Related]
56. The relationship of dopamine receptor blockade to clinical response in schizophrenic patients treated with pimozide or haloperidol.
Silverstone T; Cookson J; Ball R; Chin CN; Jacobs D; Lader S; Gould S
J Psychiatr Res; 1984; 18(3):255-68. PubMed ID: 6387105
[TBL] [Abstract][Full Text] [Related]
57. A controlled dose comparison of haloperidol in newly admitted schizophrenic patients.
Van Putten T; Marder SR; Mintz J
Arch Gen Psychiatry; 1990 Aug; 47(8):754-8. PubMed ID: 2378546
[TBL] [Abstract][Full Text] [Related]
58. Relationship of serum haloperidol levels to clinical response in schizophrenic patients.
Magliozzi JR; Hollister LE; Arnold KV; Earle GM
Am J Psychiatry; 1981 Mar; 138(3):365-7. PubMed ID: 7468835
[TBL] [Abstract][Full Text] [Related]
59. Anticonvulsants as adjuncts for the neuroleptic treatment of schizophrenic psychoses: a clinical study with beclamide.
Raptis C; Garcia-Borreguero D; Weber MM; Dose M; Bremer D; Emrich HM
Acta Psychiatr Scand; 1990 Feb; 81(2):162-7. PubMed ID: 2183543
[TBL] [Abstract][Full Text] [Related]
60. [Use and value of the therapeutic neuroleptic-bromocriptine combination in schizophrenia].
Lombertie ER; Durelle G; Fuseau A
Ann Med Psychol (Paris); 1995 Oct; 153(8):531-4. PubMed ID: 8561400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
